SAFC Pharma selected as Alzheimer's partner
SAFC Pharma has been appointed by BTG to provide chemical development services relating to BGC20-1259, a potential treatment for Alzheimer?s disease.
SAFC Pharma has been appointed by BTG to provide chemical development services relating to BGC20-1259, a potential treatment for Alzheimer's disease. BGC20-1259 is currently in Phase I clinical studies, and is a unique, multifunctional compound being developed to target the cognitive impairment and behavioural aspects of Alzheimer's disease, and to provide neuroprotection. The company's chemists will conduct process R&D studies on the synthesis of the drug to determine a suitable process for the production of sufficient quantities for clinical trials. cGMP manufacturing of the compound is anticipated by SAFC following this process development.
"We are delighted that BTG has selected SAFC as its chemical development partner for BGC20-1259," commented Frank Wicks, SAFC president. "Our preclinical chemical support expertise and extensive knowledge in this area has resulted in a positive response from the pharmaceutical industry, demonstrated by our continued growth in the chemistry services and custom manufacturing business."
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
